Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (023)

Bradley Monk; Krishnansu Tewari; Coraline Dubot; M. Valeria Caceres; Kosei Hasegawa; Ronnie Shapira-Frommer; Pamela Salman; EDUARDO Yanez; Mahmut Gümüş; Mivael Olivera Hurtado de Mendoza; Vanessa Samouëlian; Vincent Castonguay; Alexander Arkhipov; Cumhur Tekin; Kan Li; Allison Martin Nguyen; Matthew Monberg; Nicoletta Colombo; Domenica Lorusso

doi:10.1016/S0090-8258(22)01241-0

Back

Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (023)

Journal article

Peer reviewed

Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (023)

Bradley Monk, Krishnansu Tewari, Coraline Dubot, M. Valeria Caceres, Kosei Hasegawa, Ronnie Shapira-Frommer, Pamela Salman, EDUARDO Yanez, Mahmut Gümüş, Mivael Olivera Hurtado de Mendoza, …

Gynecologic oncology, Vol.166, p.S18

08/2022

DOI: https://doi.org/10.1016/S0090-8258(22)01241-0

Metrics

4 Record Views

Details

Title: Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (023)
Creators: Bradley Monk
Krishnansu Tewari
Coraline Dubot
M. Valeria Caceres
Kosei Hasegawa
Ronnie Shapira-Frommer
Pamela Salman
EDUARDO Yanez
Mahmut Gümüş
Mivael Olivera Hurtado de Mendoza
Vanessa Samouëlian
Vincent Castonguay
Alexander Arkhipov
Cumhur Tekin
Kan Li
Allison Martin Nguyen
Matthew Monberg
Nicoletta Colombo
Domenica Lorusso
Publication Details: Gynecologic oncology, Vol.166, p.S18
Identifiers: 991005969028402656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article

Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (023)

Related links

Metrics

Details